Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Our CEO Joe Wiley is a doctor by training with a deep interest in rare and debilitating diseases, who felt compelled to do something to transform the lives of patients living with these conditions. Joe gathered a team of experts, all with two things in common - experience in rare diseases and a passion to provide much-needed treatment options for these patients, and that's where Amryt Pharma started in 2015. Since then, we have acquired 3 companies, we now commercialise 3 products and have helped thousands of patients with rare, and debilitating diseases.